FDA 483 - Yuki Gosei Kogyo Co., Ltd. - July 26, 2021
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of Yuki Gosei Kogyo Co., Ltd. in Iwaki, Fukushima, Japan, a drug substance manufacturer, revealed significant deficiencies in its quality unit and laboratory control systems. Observations included a failure to implement timely corrective actions for recurring data integrity issues with Distributed Control Systems, inadequate evaluation of alarm events, and a lack of effective CAPA for repeated HPLC system suitability failures. Additionally, the firm failed to perform working sample stability studies and lacked scientific justification for discarding original samples.
ID · 8700b1bd-eea2-448e-a157-3769644beb34